Download


Prothrombin Time (PT)
Investigation Result Units Biological Reference Interval

PROTHROMBIN TIME : TEST 16.1 Seconds 11 - 13.5
PROTHROMBIN TIME: CONTROL 13.5 Seconds
TEST / CONTROL (RATIO) 1.19
CONTROL / TEST (INDEX) 0.83
I.N.R. VALUE 1.22 0.8 - 1.2

Sample type : Citrated plasma. Method : Photo Optical Clot Detection. Note : Prothrombin time (PT) is the test of choice for monitoring patients on oral anticoagulants.The international normalized ration (INR) is the recommended method for reporting prothrombin time results for control of oral anticoagulation. It is now widely accepted that the anticoagulation level and the appropriate drug regimen are best determined on the basis of the INR. INR 2.0 - 3.0 INR 3.0 - 4.0 Prophylaxis of venous thrombosis (high risk surgery) Mechanical prosthetic valves (high risk) Treatment of venous thrombosis or pulmonary embolism Prevention of recurrent myocardial infarction. Prevention of systemic embolism:-Tissue heart valves, valvular heart disease, acute myocardial infarct, valvular heart disease, atrial fibrillation Disclaimer : 1) The above result relate only to the specimens received and tested in laboratory and should be always correlate with clinical findings and other laboratory markers. 2) Improper specimen collection, handling, storage and transportation may result in false negative/Positive results.

--End Of Report--
Biochemistry
Investigation Result Units Biological Reference Interval

Creatinine 0.55 mg/dL 0.5 - 0.9
• Sample Type : Serum.
• Method : Jaffe's Kinetic- Alkaline Picrate.
Urea 22 mg/dL 16 - 38
• Sample Type : Serum.
• Method : Urease & glutamate dehydrogenase.

Sample Type: Serum Method: Jaffe's Disclaimer: 1)The above result relate only to the specimens and should be always correlate with clinical findings and other laboratory markers. 2)Improperspecimen collection, handling. Storage and transportation may result in false negative/Positive results.

--End Of Report--
SGOT / AST (Aspartate Transaminase)
Investigation Result Units Biological Reference Interval

SGOT / AST (Aspartate Transaminase) 20.7 U/L 0 - 32
• Sample Type : Serum.
• Method : NADH(without p-5-p) OR IFCC.

Disclaimer: 1)The above result relate only to the specimens and should be always correlate with clinical findings and other laboratory markers. 2)Improperspecimen collection, handling. Storage and transportation may result in false negative/Positive results.

--End Of Report--
SGPT / ALT (Alanine Aminotransferase)
Investigation Result Units Biological Reference Interval

SGPT / ALT (Alanine Aminotransferase) 25.3 U/L 0 - 33
• Sample Type : Serum.
• Method : NADH(without p-5-p) OR IFCC.

Disclaimer: 1)The above result relate only to the specimens and should be always correlate with clinical findings and other laboratory markers. 2)Improperspecimen collection, handling. Storage and transportation may result in false negative/Positive results.

--End Of Report--
P011B000403172
Download


CBC (Haemogram)
Investigation Result Units Biological Reference Interval

Haemoglobin (Hb) 13.3 gm/dL 12 - 15
Sample Type : EDTA Whole Blood
Method : Free Cyanide
Hematocrit 39.7 % 36 - 46
Sample Type : EDTA Whole Blood
Method : Calculated
RBC Count 4.49 million/cmm 4.5 - 5.5
Sample Type : EDTA Whole Blood
Method : Electrical Impedance
WBC (Total Leukocyte) Count 8340 Cells/cumm 4000 - 10000
Sample Type : EDTA Whole Blood
Method : Flow Cytometry
Platelet Count 277000 /cmm 150000 - 450000
Sample Type : EDTA Whole Blood
Method : Electrical Impedance
CBC (Haemogram)
Investigation Result Units Biological Reference Interval

Manual Platelet Count 00 /cmm
Sample Type : EDTA Whole Blood
Method : Microscopy using Leishman stain
MCV 88.5 fL 83 - 101
Sample Type : EDTA Whole Blood
Method : Calculated
MCH 29.7 pg 27 - 32
Sample Type : EDTA Whole Blood
Method : Calculated
MCHC 33.6 g/dL 31.5 - 34.5
Sample Type : EDTA Whole Blood
Method : Calculated
RDW-CV 12.8 % 11.6 - 14
Sample Type : EDTA Whole Blood
Method : Calculated
RDW-SD 45 fL 35 - 56
Sample Type : EDTA Whole Blood
Method : Calculated
MPV (Mean Platelet Volume) 9.7 fL 6 - 9.5
Sample Type : EDTA Whole Blood
Method : Calculated
PDW (Platelet Distribution Width) 16.1 % 9 - 17
Sample Type : EDTA Whole Blood
Method : Calculated
PCT 0.27 % 0.2 - 0.5
Sample Type : EDTA Whole Blood
Method : Calculated
CBC (Haemogram)
Investigation Result Units Biological Reference Interval

Neutrophils (%) 63.4 % 40 - 80
Sample Type : EDTA Whole Blood
Method : Flow Cytometry
Lymphocytes (%) 26.7 % 20 - 40
Sample Type : EDTA Whole Blood
Method : Flow Cytometry
Monocytes (%) 8 % 2 - 10
Sample Type : EDTA Whole Blood
Method : Flow Cytometry
Eosinophils (%) 1.9 % 1 - 6
Sample Type : EDTA Whole Blood
Method : Flow Cytometry
Basophils (%) 00 % 0 - 2
Sample Type : EDTA Whole Blood
Method : Flow Cytometry
Absolute Neutrophils Count 5287.56 /c.mm 2000 - 7000
Sample Type : EDTA Whole Blood
Method : Calculated
CBC (Haemogram)
Investigation Result Units Biological Reference Interval

Absolute Lymphocyte Count 2226.78 /c.mm 1000 - 3000
Sample Type : EDTA Whole Blood
Method : Calculated
Absolute Monocyte Count 667.2 /c.mm 200 - 1000
Sample Type: EDTA Whole Blood
Method: Calculated
Absolute Eosinophil Count 158.46 /c.mm 20 - 500
Sample Type : EDTA Whole Blood
Method : Calculated
Absolute Basophil Count 00 /c.mm 20 - 100
Sample Type : EDTA Whole Blood
Method : Calculated
Absolute Neutrophil/Lymphocyte Ratio 00 -- --
Sample Type : EDTA Whole Blood
Method : Calculated
Blasts (%) 00 %
Sample Type: EDTA Whole Blood
Method: Microscopy using Leishman stain
Promyelocytes (%) 00 %
Sample Type: EDTA Whole Blood
Method: Microscopy using Leishman stain
Myelocytes (%) 00 %
Sample Type: EDTA Whole Blood
Method: Microscopy using Leishman stain
Metamyelocytes (%) 00 %
Sample Type: EDTA Whole Blood
Method: Microscopy using Leishman stain
CBC (Haemogram)
Investigation Result Units Biological Reference Interval

Band form Cells (%) 00 %
Sample Type: EDTA Whole Blood
Method: Microscopy using Leishman stain
RBC Morphology Normocytic Normochromic - -
Sample Type: EDTA Whole Blood
Method: Microscopy using Leishman stain
WBC Morphology Total leucocyte count within normal limits - -
Sample Type: EDTA Whole Blood
Method: Microscopy using Leishman stain
Platelets Adequate -- -
Sample Type: EDTA Whole Blood
Method: Microscopy using Leishman stain
CBC (Haemogram)
Clinical Significance:
Test Causes of Low Abnormal Causes of High Abnormal
White blood cell count (WBC) Autoimmune diseases, immunosuppression, bone marrow failure, chemotherapy, viral infections Infection, inflammation, leukemia, intense exercise, stress, corticosteroids
Lymphocytes, absolute (LY, abs) or percentage (LY, pct) Immunosuppression, HIV-AIDS, bone marrow failure, chemotherapy Viral infections, leukemia, lymphoma
Monocytes, absolute (MO, abs) or percentage (MO, pct) Immunosuppression, bone marrow failure, chemotherapy Chronic infections, autoimmune diseases, leukemia
Granulocytes, absolute (GR, abs) or percentage (GR, pct) Immunosuppression, bone marrow failure, chemotherapy Infection, inflammation, leukemia, intense exercise, stress, corticosteroids
Neutrophils, absolute (NE, abs) or percentage (NE, pct) Immunosuppression, bone marrow failure, chemotherapy Infection, inflammation, leukemia, intense exercise, stress, corticosteroids
Eosinophils, absolute (EOS, abs) or percentage (EOS, pct) Sepsis, Alcohol Intoxication, Stress, Increased Cortisol Parasitic infections, Active Allergic Response
Basophils, absolute (BAS, abs) or percentage (BAS, pct) Stress, Chemotherapy, Radiotherapy, Corticosteroid Chronic Inflammation, Autoimmune Disease, Leukemia
Red blood cell count (RBC) Iron, vitamin B12, or folate deficiency; bone marrow damage; leukemia or lymphoma; acute or chronic blood loss; red blood cell hemolysis Dehydration, renal problems, pulmonary disease, congenital heart disease, polycythemia vera
CBC (Haemogram)
Clinical Significance:
Test Causes of Low Abnormal Causes of High Abnormal
Hemoglobin (HgB) Iron, vitamin B12, or folate deficiency; bone marrow damage; leukemia or lymphoma; acute or chronic blood loss; red blood cell hemolysis Dehydration, renal problems, pulmonary disease, congenital heart disease, polycythemia vera
Hematocrit (PCV) Iron, vitamin B12, or folate deficiency; bone marrow damage; leukemia or lymphoma; acute or chronic blood loss; red blood cell hemolysis Dehydration, renal problems, pulmonary disease, congenital heart disease, polycythemia vera
Mean corpuscular volume (MCV) Iron deficiency, Thalassemia, lead poisoning Vitamin B12 or folate deficiency, Chronic liver disease
Mean corpuscular hemoglobin (MCH) Iron deficiency, Thalassemia Vitamin B12 or folate deficiency, Macrocytosis
Mean corpuscular hemoglobin concentration (MCHC) Iron deficiency, Thalassemia Sickle cell disease, hereditary spherocytosis
Red cell distribution width (RDW) Generally not a concern Iron deficiency, vitamin B12 or folate deficiency, recent blood loss
Platelet count (PLT) Bone marrow failure, chemotherapy, viral infections, lupus, pernicious anemia (due to vitamin B12 deficiency), leukemia or lymphoma, sequestration in the spleen, certain medications Leukemia, myeloproliferative disorders (which cause blood cells to grow abnormally in bone marrow), inflammatory conditions
Mean platelet volume (MPV) Aplastic anemia, thrombocytopenia, bone marrow suppression Certain inherited disorders

Disclaimer: The above result relate only to the specimens and should be always correlate with clinical findings and other laboratory markers.

--End Of Report--
Glucose (Blood Sugar), Random
Investigation Result Units Biological Reference Interval

Glucose (Blood Sugar), Random 81.1 mg/dl 70 - 140
• Sample Type : Fluoride plasma.
• Method : Hexokinase.


Interpretation -

The American Diabetes Association’s (ADA’s) Standards of Medical Care in Diabetes 2022
Criteria for the Screening and Diagnosis of Prediabetes and Diabetes


Test Prediabetes Diabetes
HbA1c 5.7–6.4% (39–47 mmol/mol)* 6.5% (48 mmol/mol)†
Fasting plasma glucose 100–125 mg/dL (5.6–6.9 mmol/L)* 126 mg/dL (7.0 mmol/L)†
2-hour plasma glucose during 75-g OGTT 140–199 mg/dL (7.8–11.0 mmol/L)* 200 mg/dL (11.1 mmol/L)†
Random plasma glucose 200 mg/dL (11.1 mmol/L)‡

Adapted from Tables 2.2 and 2.5 in the complete 2022 Standards of Care.*
For all three tests, risk is continuous, extending below the lower limit of the range and becoming disproportionately greater at the higher end of the range.†
In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate samples‡
Only diagnostic in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis.